CAMBRIDGE, Mass.--(

马萨诸塞州剑桥--(

BUSINESS WIRE

商业热线

)--

)--

Parabilis Medicines

Parabilis药物

(formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer, today announced the presentation of a trial-in-progress poster on the Company’s first-in-human clinical trial evaluating FOG-001, the first and only direct inhibitor of β-catenin.

（原Fog Pharmaceuticals）是一家临床阶段的生物制药公司，致力于为癌症患者创造非凡的药物，今天宣布在该公司第一次评估Fog-001的人体临床试验中展示正在进行的试验海报，Fog-001是第一个也是唯一的β-连环蛋白直接抑制剂。

TCF4

TCF4型

, at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place in San Francisco from January 23-25, 2025.

，于2025年1月23日至25日在旧金山举行的美国临床肿瘤学会（ASCO）胃肠道癌症研讨会上。

FOG-001 is being evaluated in a Phase 1/2 clinical trial (

FOG-001正在1/2期临床试验中进行评估(

NCT05919264

NCT05919264 型号

). The multicenter, open-label, non-randomized trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of FOG-001 in patients with microsatellite stable colorectal cancer (MSS CRC) and other solid tumors with Wnt pathway activating mutations (WPAM+).

)。这项多中心，开放标签，非随机试验旨在评估FOG-001在微卫星稳定型结直肠癌（MSS CRC）和其他具有Wnt途径激活突变的实体瘤患者中的安全性，耐受性，药代动力学，药效学和抗肿瘤活性（WPAM+）。

The trial plans to enroll patients in multiple third-line MSS CRC cohorts as both a monotherapy and in combination with FOLFOX+bevacizumab, anti-PD-1/PD-L1, or trifluridine/tipiracil+bevacizumab..

该试验计划将患者纳入多个三线MSS CRC队列，作为单一疗法，并与FOLFOX+贝伐单抗，抗PD-1/PD-L1或三氟尿苷/替吡拉西+贝伐单抗联合使用。。

At the 2025 J.P. Morgan Healthcare Conference, Parabilis

在2025年摩根大通医疗保健会议上，Parabilis

provided an update

提供了更新

on the trial’s progress. The Company disclosed that more than 60 patients with locally advanced or metastatic solid tumors have been dosed with FOG-001 to date, and that early clinical data demonstrate monotherapy antitumor activity and in-tumor target engagement. Preliminary Phase 1/2 data are expected to be shared publicly in 2025..

关于审判的进展。该公司透露，迄今为止，已有60多名局部晚期或转移性实体瘤患者服用了FOG-001，早期临床数据表明单药治疗具有抗肿瘤活性和肿瘤靶向作用。初步的1/2期数据预计将在2025年公开共享。。

Full details of the poster are as follows:

海报的全部细节如下：

Title:

标题：

“A Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors”

“FOG-001（一种一流的直接β-连环蛋白：TCF抑制剂）在结直肠癌，肝细胞癌和其他局部晚期或转移性实体瘤患者中的1/2期研究”

Abstract Number:

摘要编号：

TPS322

TPS322

Presentation Date and Time:

January 25, 2025, 7:00-7:55 a.m. PST

2025年1月25日，太平洋标准时间上午7:00-7:55

Session Information:

会话信息：

Trials in Progress Poster Session C

正在进行的试验海报会议C

Location:

地点：

Level 1, West Hall, Moscone West

莫斯科内西区西大厅1楼

About FOG-001

关于FOG-001

FOG-001 is an investigational first-in-class competitive inhibitor of β-catenin interactions with the T-cell factor (TCF) family of transcription factors, and is currently in clinical development. By directly targeting the β-catenin

FOG-001是β-连环蛋白与T细胞因子（TCF）转录因子家族相互作用的研究性一流竞争性抑制剂，目前正在临床开发中。通过直接靶向β-连环蛋白

TCF4

TCF4型

protein-protein interaction, FOG-001 is intended to block the Wnt signaling pathway irrespective of the various APC and beta-catenin mutations that typically drive disease.

蛋白质-蛋白质相互作用，FOG-001旨在阻断Wnt信号通路，而与通常驱动疾病的各种APC和β-连环蛋白突变无关。

FOG-001 combines key features that distinguish it from previously reported Wnt/β-catenin pathway modulators: FOG-001 acts inside the cell where it binds directly to the key oncogenic driver β-catenin; and FOG-001 blocks the Wnt pathway at the most downstream node, disrupting the interaction between β-catenin and the transcription factor TCF, thereby abrogating the signal transmission by which Wnt pathway mutations are believed to drive oncogenesis.

FOG-001结合了将其与先前报道的Wnt/β-连环蛋白途径调节剂区分开的关键特征：FOG-001在细胞内起作用，直接与关键的致癌驱动因子β-连环蛋白结合；FOG-001阻断了最下游节点的Wnt通路，破坏了β-连环蛋白与转录因子TCF之间的相互作用，从而消除了Wnt通路突变被认为驱动肿瘤发生的信号传递。

FOG-001 is currently being evaluated in a first-in-human Phase 1/2 clinical trial in patients with locally advanced or metastatic solid tumors..

FOG-001目前正在局部晚期或转移性实体瘤患者的首次人体1/2期临床试验中进行评估。。

About Parabilis Medicines (Formerly Fog Pharmaceuticals)

关于Parabilis Medicines（以前叫Fog Pharmaceuticals）

Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through its Helicon

Parabilis Medicines是一家临床阶段的生物制药公司，致力于为癌症患者创造非凡的药物。通过它的螺旋

discovery platform, Parabilis is engineering precisely tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. This versatile platform enables applications for Helicons across three main areas: functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals..

。这个多功能平台可以在三个主要领域应用螺旋体：细胞内蛋白质-蛋白质相互作用的功能抑制剂，靶向蛋白质降解物和靶向放射性药物。。

Parabilis is advancing a pipeline of first-in-class programs across these three domains, led by FOG-001, its clinical-stage β-catenin

Parabilis正在推进这三个领域的一流项目，由其临床阶段β-连环蛋白FOG-001领导

TCF4

TCF4型

inhibitor. Parabilis is headquartered in Cambridge, Mass., and is well-capitalized, with more than $500 million raised to date from leading life sciences investors. For more information, please visit:

抑制剂。Parabilis总部位于马萨诸塞州剑桥市，资本充足，迄今已从领先的生命科学投资者那里筹集了5亿多美元。有关更多信息，请访问：

www.parabilismed.com

www.parabilismed.com